23 - LONG-TERM OUTCOMES FROM THE PHASE 3 OCEAN (OP-103) STUDY: MELPHALAN FLUFENAMIDE (MELFLUFEN) AND DEXAMETHASONE VERSUS POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA

36 - TALQUETAMAB + POMALIDOMIDE IN PATIENTS WITH RELAPSE/REFRACTORY MULTIPLE MYELOMA: SAFETY AND PRELIMINARY EFFICACY RESULTS FROM THE PHASE 1B MONUMENTAL-2 STUDY

12 - EFFICACY AND SAFETY IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA AND 1–3 PRIOR LINES WHO RECEIVED A SINGLE INFUSION OF CILTACABTAGENE AUTOLEUCEL AS STUDY TREATMENT IN THE PHASE 3 CARTITUDE-4 TRIAL

13 - EFFICACY AND SAFETY OF LESS FREQUENT/LOWER INTENSITY DOSING OF TALQUETAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RESULTS FROM THE PHASE 1/2 MONUMENTAL-1 STUDY

7 - CLINICAL OUTCOMES OF SUBSEQUENT THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FOLLOWING TALQUETAMAB TREATMENT: ANALYSES FROM THE PHASE 1/2 MONUMENTAL-1 STUDY

22 - LONGITUDINAL CORRELATIVE PROFILES OF RESPONDERS, NONRESPONDERS, AND THOSE WITH RELAPSE ON TREATMENT WITH TECLISTAMAB IN THE MAJESTEC-1 STUDY OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE-RISK OR HIGH-RISK SMOLDERING MULTIPLE MYELOMA (SMM): FINAL ANALYSIS OF THE PHASE 2 CENTAURUS STUDY

PHASE 2 CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL IN MULTIPLE MYELOMA AND 1–3 PRIOR LINES (COHORT A) AND WITH EARLY RELAPSE AFTER FRONTLINE TREATMENT (COHORT B)

UPDATED RESULTS OF TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH PRIOR EXPOSURE TO T-CELL REDIRECTING THERAPIES: RESULTS OF THE PHASE 1/2 MONUMENTAL-1 STUDY